Post di Nerina Denaro

🛡️ Generous Margins for Better Outcomes With the NanoKnife System, you can expand treatment margins without negatively impacting the rates of erectile function and incontinence in men. Experience improved prostate tumor treatment with a focus on preserving a man’s quality of life. (1, 2) Contact us to learn more: https://lnkd.in/gbXwCYKW Risk Info: https://lnkd.in/gFNG_pA 1. Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: A biopsy-monitored prospective cohort. European Urology Oncology. 2020;3(3):283-290. doi:10.1016/j.euo.2019.04.008 2. de la Rosette, Jean et al. “A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.” The Journal of urology vol. 209,2 (2023): 347-353. doi:10.1097/JU.000000000000305

We are honored to participate in the #Oligocare study organized by the European Society for Radiotherapy and Oncology (ESTRO) and EORTC - European Organisation for Research and Treatment of Cancer Ente Ecclesiastico Ospedale Generale Regionale 'F. MIULLI' stands out as the only center in southern Italy participating in this protocol. The research indicated that radiotherapy, along with medical therapy, effectively treats even advanced forms of cancer, comparable to surgery but with less impact on patients. Oligocare is a cohort of the #E2RADIatE platform. We are actively recruiting patients diagnosed with oligometastatic breast, lung, colon, rectal, and prostate cancer. Join ESTRO and EORTC in the fight against cancer, contributing to advancements that could benefit many. Università LUM Medipass - Ergéa Group

Incorporation of biomarker-directed approaches in RT for breast cancer may hold promise for personalized treatment This personalized RT approach may be associated with improved clinical outcomes and quality of life and facilitate decision-making for people with breast cancer. #radonc #radiotherapycures #radiationtherapysaveslifes

🎥 La Dottoressa Toss e il Dottor Licata presentano le nuove prospettive di trattamento nel carcinoma mammario HR+ HER2-low e HER2-ultralow Il recente studio Destiny-Breast06 ha introdotto novità significative nel trattamento del carcinoma mammario, evidenziando un vantaggio nell'impiego di Trastuzumab-Deruxtecan in prima linea per le pazienti con espressione HER2-low e HER2-ultralow a seguito del fallimento della terapia endocrina. Questi risultati, presentati e discussi ai congressi ASCO ed ESMO 2024, hanno suscitato un ampio dibattito, stimolando la discussione tra gli esperti sull'opportunità di modificare le linee terapeutiche per alcuni sottogruppi di pazienti. In questo video, la Dottoressa Toss e il Dottor Licata, Responsabili dell'evento "What is low?" svoltosi a Bologna il 3 ottobre 2024, approfondiscono i risultati dello studio, le loro implicazioni e discutono le future prospettive terapeutiche per il carcinoma mammario HER2-low. 🔍 Guarda il video per scoprire le nuove prospettive di trattamento per le pazienti con carcinoma mammario HER2-low e ultralow. #BreastCancer #ASCO2024 #ESMO2024 #TDXd #HER2Low #HER2Ultralow #DestinyBreast06 #CarcinomaMammario #TrastuzumabDeruxtecan 🎥 Dr. Toss and Dr. Licata present new treatment perspectives for HR+ HER2-low and HER2-ultralow breast cancer The recent Destiny-Breast06 study has introduced significant advancements in breast cancer treatment, demonstrating the benefits of using Trastuzumab-Deruxtecan as a first-line option for patients with HER2-low and HER2-ultralowexpression following endocrine therapy failure. These findings, presented and discussed at the ASCO and ESMO 2024 congresses, have sparked a wide-ranging debate, encouraging discussions among experts about the potential to redefine therapeutic approaches for specific patient subgroups. In this video, Dr. Toss and Dr. Licata, chairpersons in the "What is low?" event held in Bologna on October 3, 2024, delve into the study’s findings, their implications, and future therapeutic perspectives for HER2-low breast cancer. 🔍 Watch the video to explore new treatment perspectives for patients with HER2-low and ultralow breast cancer. #BreastCancer #ASCO2024 #ESMO2024 #TDXd #HER2Low #HER2Ultralow #DestinyBreast06 #TrastuzumabDeruxtecan

🇨🇭Next stop...Basel! ✈️ Meet our team at the 2024 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology in Basel from 11-14 October and learn more about our recent developments in Oncology and beyond! 📍Stop by our booth 1.05 and get to experience firsthand our New Generation SOPHiA DDM™ Platform and learn more about our different applications and offerings in oncology, rare diseases, and inherited disorders. We can't wait to meet you! #DGHO #DGHO2024 #oncology #hematology #medicaloncology #precisionmedicine